Tibotec Pharmaceuticals Ltd.

Medivir Ab

Janssen R&d Ireland

Janssen Sciences Ireland Uc

Medivar Ab

Janssen Pharmaceuticals, Inc.

Tibotec Bvba

Tibotec Pharmaceuticals Ltd. Co

Medivir Aktiebolag

Herman Augustinus De Kock

Dominique Louis Nestor Ghislain Surleraux

Pierre Jean-Marie Bernard Raboisson

Kenneth Simmen

Abdellah Tahri

Sandrine Marie Helene Vendeville

Karl Magnus Nilsson

Bengt Bertil Samuelsson

Lili Hu

Piet Tom Bert Paul Wigerinck

Åsa Annica Kristina Rosenquist

Wim Gaston Verschueren

Per-Ola Mikael Johansson

Wim Van De Vreken

Vladimir Kirillovich Ivanov

Mikael Pelcman

Tim Hugo Maria Jonckers

Stefaan Julien Last

Marie-Pierre T M M G De Bethune

David Craig McGowan

Dmitry Antonov

Anna Karin Gertrud Linnea Belfrage

Paul Jozef Gabriel Maria Boonants

Anna Karin Gertrud Linea Belfrage

Pia Kahnberg

Hans Kristian Wallberg

Gerben Albert Van 't Klooster

Inge Dierynck

Björn Olof Classon

Montserrat Erra Solà

Judith Baumeister

Lieven Elvire Colette Baert

Sandrine Vendeville

Roger Petrus Gerebern Vandecruys

David Craig Mc Gowan

Lourdes Salvador Odén

Bernhard Joanna Bernard Vergouwen

Mats Stefan Lindström

Pierre Jean-Marie Raboisson

Sandra De Meyer

Wim Albert Alex Aelterman

Carl Erik Daniel Jönsson

Pierre Jean-Marie Bernard Rabiosson

Horst Jürgen Wähling

Karin Charlotta Lindquist

Susana Ayesa Alvarez

Samuel Leo Christiaan Moors

Jan Octaaf Antoon De Kerpel

Ismet Dorange

Daniel Getman

Bengt Bertril Samuelsson

Marie-Pierre De Bethune

Marieke Christiane Johanna Voets

Vladimir Ivanov

Yvan Simonnet

Marieke Christiane Johanna Diepenbeek Voets

Anna Karin Belfrage

Peter Jozef Maria Van Remoortere

Michael Pelcman

Sven Crister Sahlberg

ÅSa Annica Kristina Rosenquist

Piet Piet Tom Bert Paul Wigerinck

Pia Cecilia Kahnberg

Åsa Annica Kristina Rosenquist

Per-Ola Mikael c/o Medivir Ab Johansson

Karl Magnus c/o Medivir Ab Nilsson

Åsa Annica Kristina c/o Medivir Ab Rosenquist

Vladimir c/o Medivir Ab Ivanov

Michael c/o Medivir Ab Pelcman

Bengt Bertil c/o Medivir Ab Samuelsson

Anna Karin Gertrud L c/o Medivir Ab Belfrage

Judith Eva Baumeister

Horst Jürgen WÄHLING

Gerben Albert Eleutherius Van 'T Klooster

Paul Jozef Boonants

Wim Albert Aelterman

Piet Tom Wigerinck

Dominique Louis Surleraux

Tim Hugo Jonckers

Kenneth Alan Simmen

Inhibitors of HCV replication of formula (I) 

Macrocyclic inhibitors of hepatitis C virus

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein

Inhibitors of HCV replication of formula (I) and the salts and stereoisomers thereof, wherein

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond;

The amorphous form of the sodium salt of the macrocyclic inhibitor of HCV of formula: as well as processes for manufacturing this salt.

Amorphous salt of a macrocyclic inhibitor of HCV

Inhibitors of HCV replication of formula (I) the N-oxides, salts, and stereochemically isomeric forms thereof, wherein each dashed line (represented by) represents an optional double bond;

Inhibitors of HCV replication of formula (I) whereinW is a heterocycle of formula and the remaining variables are as defined in the specification.

The present invention relates to a process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate as well as novel intermediates for use in said process. (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate is particularly useful as an HIV protease inhibitor.

Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate

A method for improving the pharmacokinetics of drugs, which are metabolized by cytochrome P450 monooxygenase is disclosed. More specifically it relates to a method for improving the pharmacokinetics of retroviral protease inhibitors and in particular for improving the pharmacokinetics of human immunodeficiency virus (HIV) protease inhibitors. A pharmaceutical composition and its use in the manufacture of a medicament for the inhibition or treatment of an HIV infection or AIDS in a human being are also part of the invention.

Use of a sulfonamide compound for improving the pharmacokinetics of a drug

Macrocylic inhibitors of hepatitis C virus

The present invention concerns lysine related derivatives, their use as protease inhibitors, in particular as HIV aspartyl protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present lysine related derivatives with another anti retroviral agent. It further relates to their use in assays as reference compounds or as reagents.

Lysine related derivatives as HIV aspartyl protease inhibitors

Growing community of inventors

Arendonk, Belgium

Herman Augustinus De Kock